SCHEMBL12468524

SCHEMBL12468524

CN(C)C(=O)c1cccc(-c2nccs2)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.52
ABL1 P00519 2/20 0.50
BCR P11274 2/20 0.50
HPGD P15428 1/20 0.50
NTRK1 P04629 1/20 0.47
PDPK1 O15530 1/20 0.47
FYN P06241 3/20 0.46
HDAC2 Q92769 1/20 0.46
ERN1 O75460 2/20 0.46
CYP3A4 P08684 1/20 0.44
MAP4K1 Q92918 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
FFAR1 O14842 1/20 0.43
CYP2A6 P11509 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
MTOR P42345 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13043934 0.84 KAT6A (0.55) KAT6AABL1BCRNTRK1PDPK1
SCHEMBL30850854 0.82 KAT6A (0.60) KAT6AABL1BCRHPGDNTRK1
SCHEMBL939202 0.82 KAT6A (0.60) KAT6AABL1BCRHPGDNTRK1
SCHEMBL2303493 0.81 KAT6A (0.55) KAT6AABL1BCRNTRK1PDPK1
SCHEMBL6031253 0.81 KAT6A (0.55) KAT6AABL1BCRNTRK1PDPK1
SCHEMBL3741524 0.80 KAT6A (0.55) KAT6AABL1BCRHPGDNTRK1
SCHEMBL2733047 0.80 KAT6A (0.61) KAT6AABL1BCRHPGDNTRK1
SCHEMBL5078585 0.77 KAT6A (0.49) KAT6AHPGDNTRK1PTGDR2
SCHEMBL15805858 0.76 PDPK1 (0.72) KAT6ANTRK1PDPK1HDAC2PTGDR2
SCHEMBL28461611 0.75 SIRT2 (0.70) KAT6AHPGDNTRK1HDAC2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110182854-A1 HCV PROTEASE INHIBITORS SEQUOIA PHARMACEUTICALS, INC. (US) 2011-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110182854-A1 HCV PROTEASE INHIBITORS SERPINB1, CTSC, HPN KAT6A 3545/4885ABL1 995/4885BCR 3983/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.